2-氨基-5-氯-N-甲基苯甲酰胺 | 19178-37-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-氨基-5-氯-N-甲基苯甲酰胺
• 英文名称: 2-amino-5-chloro-N-methylbenzamide
• CAS: 19178-37-1
• 化学式: C₈H₉ClN₂O
• mdl: MFCD01666699
• 分子量: 184.625
• InChiKey: SHOFEQJWALLTLQ-UHFFFAOYSA-N

物化性质

• 沸点：
  334.9±32.0 °C(Predicted)
• 密度：
  1.281±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.125
• 拓扑面积：
  55.1
• 氢给体数：
  2
• 氢受体数：
  2

安全信息

• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-氨基-5-氯-N-甲基苯甲酰胺 在 Oxone 、 溶剂黄146 作用下， 以 二氯甲烷 、 水 、 甲苯 为溶剂， 生成
  参考文献：
  名称：

  Azobenzene-diamides as Photopharmacological Ligands for Insect Ryanodine Receptor

  摘要：

  Photoresponsive ligands are powerful tool compounds for studying receptor function with spatiotemporal resolution. However, to the best of our knowledge, such a ligand is not available for the ryanodine receptor (RyR). Herein, we present a photochromic ligand (PCL) for insect RyR by decorating chlorantraniliprole (CHL) with photoswitchable azobenzene (AB). We demonstrated that one potent ligand, named ABCHL13, shows light-induced reversible trans-cis isomerization and 3.5-fold insecticidal activity decrease toward oriental armyworm (Mythimna separata) after UV-light irradiation, that is, trans-ABCH13 has higher activity than the cis-ABCH13. ABCHL13 enables optical control over intracellular Ca²⁺ release in dorsal unpaired median (DUM) neurons of M. separata and American cockroach (Periplaneta americana) and cardiac function of P. americana. Our results provide a first photopharmacological toolkit that is applicable to light-dependent regulation of RyR and heart beating.

  DOI：

  10.1021/acs.jafc.0c03272
• 作为产物：
  描述：

  2-氨基-5-氯苯甲酸 在 N,N-二异丙基乙胺 、 甲胺 作用下， 生成 2-氨基-5-氯-N-甲基苯甲酰胺
  参考文献：
  名称：

  PYRIMIDINE COMPOUND AS AXL INHIBITOR

  摘要：

  本发明公开了一种嘧啶化合物作为AXL抑制剂。嘧啶化合物的结构如通用公式I所示，各取代基的定义如说明书所述。本发明还提供了一种嘧啶化合物的制备方法。本发明的嘧啶化合物具有显著的AXL抑制活性，可用于作为AXL抑制剂。

  公开号：

  EP4163278A1

文献信息

• [EN] TRIAZOLE COMPOUNDS USEFUL IN THERAPY<br/>[FR] COMPOSES DE TRIAZOLE UTILISES EN THERAPIE
  申请人：PFIZER LTD

  公开号：WO2004074291A1

  公开（公告）日：2004-09-02

  A compound of formula (I), or a pharmaceutically acceptable derivative thereof, wherein V represents -(CH2)d(O)e-, -CO-, or -CH(C1-6 alkyl)-; W is -0-, -S(O)a , or -N(R1')-R1 represents H, C 1-6 alkyl, (CH2)bCOR2, CO(CH2)bNR2R3, S02R2, (CH2 )cOR2, (CH2)c,NR2R3, or (CH2)bhet1; het1 represents a saturated or unsaturated heterocycle of from 3 to 8 atoms containing one or more heteroatoms selected from O, N, or S, optionally substituted with C 1-6 alkyl; X and Y independently represent H, C 1-6 alkyl, halogen, OH, CF3, OCF3, OR4; Z represents -(CH2)f(O)g , -CO- or -CH(C 1-6 alkyl)-; Ring A represents a 4-7 membered, saturated N-containing heterocycle, optionally substituted with OH, and in which optionally at least one ring N is substituted with O;Ring B represents phenyl or a 4-7 membered unsaturated N-containing heterocycle, optionally substituted with OH, halogen, CN, CONH2, CF3, OCF3, and in which optionally at least one ring N is substituted with O; R2 and R3 independently represent H, C 1-6 alkyl [optionally substituted with OH, halogen,N(C 1.6 alkyl)2, or C 1.6 alkyloxy], C 1.6 alkyloxy, N(C 1-6 alkyl)2, or [C 3-8 cycloalkyl]; or R2 and R3, together with the nitrogen atom to which they are attached independently represent a heterocycle of from 3 to 8 atoms, optionally substituted with C 1-6 alkyl;R4 represents straight or branched C 1-6 alkyl, a and c independently represent 0, 1, or 2; b, e and g independently represent 0 or 1; d and f independently represent 1 or 2;are useful in the treatment of dysmenorrhoea.

  式(I)的化合物，或其药学上可接受的衍生物，其中V代表-(CH2)d(O)e-, -CO-,或-CH(C1-6烷基)-；W为-0-, -S(O)a,或-N(R1')-R1代表H，C1-6烷基，(CH2)bCOR2，CO(CH2)bNR2R3，S02R2，(CH2)cOR2，(CH2)c,NR2R3，或(CH2)bhet1；het1代表一个饱和或不饱和的含有3至8个原子的杂环，其中含有一个或多个从O、N或S中选择的杂原子，可选择地用C1-6烷基取代；X和Y独立地代表H，C1-6烷基，卤素，OH，CF3，OCF3，或OR4；Z代表-(CH2)f(O)g，-CO-或-CH(C1-6烷基)-；环A代表一个4-7成员的饱和N-含杂环，可选择地用OH取代，并且其中可选择地至少一个环N用O取代；环B代表苯或一个4-7成员的不饱和N-含杂环，可选择地用OH，卤素，CN，CONH2，CF3，OCF3取代，并且其中可选择地至少一个环N用O取代；R2和R3独立地代表H，C1-6烷基[可选择地用OH，卤素，N(C1-6烷基)2，或C1-6烷氧基取代]，C1-6烷氧基，N(C1-6烷基)2，或[C3-8环烷基]；或R2和R3，连同它们附着的氮原子，独立地代表一个含有3至8个原子的杂环，可选择地用C1-6烷基取代；R4代表直链或支链C1-6烷基，a和c独立地代表0，1，或2；b，e和g独立地代表0或1；d和f独立地代表1或2；在痛经的治疗中是有用的。
• [EN] PYRIDINE COMPOUNDS<br/>[FR] COMPOSÉS PYRIDINES
  申请人：ASTRAZENECA AB

  公开号：WO2009153589A1

  公开（公告）日：2009-12-23

  The present invention relates to compounds that inhibit of focal adhesion kinase function, processes for their preparation, pharmaceutical compositions containing them as the active ingredient, to their use as medicaments and to their use in the manufacture of medicaments for use in the treatment in warm-blooded animals such as humans of diseases such as cancer.

  本发明涉及抑制细胞焦点粘附激酶功能的化合物，其制备方法，含有其作为活性成分的药物组合物，以及它们作为药物的用途，以及用于制造用于治疗温血动物（如人类）癌症等疾病的药物。
• Two-Directional Approach for the Rapid Synthesis of 2,4-Bis-Aminoaryl Pyridine Derivatives
  作者：Rémy Morgentin、Bernard Barlaam、Kevin Foote、Lorraine Hassall、Janet Hawkins、Clifford D. Jones、Antoine Le Griffon、Aurelien Peru、Patrick Plé

  DOI：10.1080/00397911.2010.520403

  日期：2012.1.1

  pyridine compounds from a common starting material. The C-4/C-2 approach uses palladium-mediated coupling reactions to sequentially functionalize C-4 and then C-2. An alternative C-2/C-4 route uses a regioselective SNAr reaction to first substitute at C-2 then subsequently at C-4 by a palladium-mediated reaction. Both approaches have been used successfully to provide a range of 2,4-bis-aminoaryl pyridine

  摘要 我们同时开发了两种不同的方法，以从常见的起始材料中快速获取 2,4-双氨基芳基吡啶化合物。C-4/C-2 方法使用钯介导的偶联反应依次功能化 C-4，然后是 C-2。另一种 C-2/C-4 路线使用区域选择性 SNAr 反应，首先在 C-2 处取代，然后在 C-4 处通过钯介导的反应进行取代。两种方法均已成功用于提供一系列 2,4-双-氨基芳基吡啶化合物。图形概要
• [EN] HALOGENATED ANALOGUES OF ANTI-FIBROTIC AGENTS<br/>[FR] ANALOGUES HALOGÉNÉS D'AGENTS ANTIFIBROTIQUES
  申请人：FIBROTECH THERAPEUTICS PTY LTD

  公开号：WO2009079692A1

  公开（公告）日：2009-07-02

  The present invention relates to halogenated compounds of formula (I) with the substituents as described within the specification. The compounds may be useful as anti-fibrqtic agents. The present invention also relates to methods for their preparation.

  本发明涉及具有规定的取代基的式(I)的卤代化合物。这些化合物可能作为抗纤维化剂有用。本发明还涉及它们的制备方法。
• Synthesis of 2-aryl quinazolinones <i>via</i> iron-catalyzed cross-dehydrogenative coupling (CDC) between N–H and C–H bonds
  作者：Yoonkyung Jang、Seok Beom Lee、Junhwa Hong、Simin Chun、Jeeyeon Lee、Suckchang Hong

  DOI：10.1039/d0ob00866d

  日期：——

  describe the direct synthesis of quinazolinones via cross-dehydrogenative coupling between methyl arenes and anthranilamides. The C–H functionalization of the benzylic sp3 carbon is achieved by di-t-butyl peroxide under air, and the subsequent amination–aerobic oxidation process completes the annulation process. Iron catalyzed the whole reaction process and various kinds of functional groups were tolerated

  在这里，我们描述了通过甲基芳烃和邻氨基苯甲酰胺之间的交叉脱氢偶联直接合成喹唑啉酮。苄sp。的C-H官能化3碳被二-实现吨丁基过氧化物在空气下，和随后的胺化需氧氧化过程完成环过程。铁催化了整个反应过程，在反应条件下可耐受各种官能团，提供了31种使用甲基芳烃衍生物的2-芳基喹唑啉酮实例，收率为57–95％。合成潜力已通过含芳基杂环的额外合成得到证明。